ArticleVaccine: X2023

Corrigendum to "Safety and immunogenicity of mRNA-LNP COVID-19 vaccine CVnCoV in Latin American adults: A phase 2 randomized study" [Vaccine: X 11 (2022) 100189].

Xavier Sáez-Llorens et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.